JETREA (ThromboGenics Inc.)
Welcome to the PulseAid listing for the JETREA drug offered from ThromboGenics Inc.. This Proteolytic Enzyme [EPC],Peptide Hydrolases [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | ThromboGenics Inc. |
NON-PROPRIETARY NAME: | ocriplasmin |
SUBSTANCE NAME: | OCRIPLASMIN |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Proteolytic Enzyme [EPC],Peptide Hydrolases [Chemical/Ingredient] |
ROUTE: | INTRAVITREAL |
DOSAGE FORM: | INJECTION, SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2017-09-18 |
END MARKETING DATE: | 0000-00-00 |
JETREA HUMAN PRESCRIPTION DRUG Details:
Item Description | JETREA from ThromboGenics Inc. |
LABELER NAME: | ThromboGenics Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 1.25(mg/mL) |
START MARKETING DATE: | 2017-09-18 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 24856-002_aefdde09-1562-4bb0-bb6e-d4f61d0c4ecb |
PRODUCT NDC: | 24856-002 |
APPLICATION NUMBER: | BLA125422 |
Other OCRIPLASMIN Pharmaceutical Manufacturers / Labelers: